Vimalanand S Prabhu
Overview
Explore the profile of Vimalanand S Prabhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monberg M, Keefe S, Karantza V, Tryfonidis K, Toker S, Mejia J, et al.
Oncol Ther
. 2024 Oct;
12(4):701-734.
PMID: 39453600
Breast and gynecologic cancers are common across the world and are associated with substantial societal and economic burden. Pembrolizumab was among the first immune checkpoint inhibitors targeting programmed cell death...
2.
Prabhu V, Kponee-Shovein K, Cheng M, Hong J, Song Y, Sun Y, et al.
J Med Econ
. 2024 Oct;
27(1):1410-1420.
PMID: 39435465
Objectives: To elucidate unmet needs in high-risk endometrial cancer (EC), this study described perioperative treatment patterns in Medicare beneficiaries with high-risk EC and quantified the impact of disease recurrence on...
3.
Zhang J, Kelkar S, Prabhu V, Ogando Y, Verma R, Grall V, et al.
Future Oncol
. 2024 Aug;
20(34):2637-2645.
PMID: 39119643
The treatment patterns and clinical outcomes in recurrent/advanced endometrial cancer in Europe are not well known. Endometrial Cancer Health Outcomes-Europe-First-Line is a multicenter, retrospective chart review study conducted in the...
4.
Kelkar S, Prabhu V, Zhang J, Ogando Y, Roney K, Verma R, et al.
Arch Gynecol Obstet
. 2024 Jul;
310(4):2281.
PMID: 39001889
No abstract available.
5.
Kelkar S, Prabhu V, Zhang J, Ogando Y, Roney K, Verma R, et al.
Arch Gynecol Obstet
. 2024 Apr;
309(6):2833-2841.
PMID: 38634898
Purpose: To assess the real-world prevalence of microsatellite instability (MSI)/mismatch repair (MMR) testing and related tumor status in recurrent/advanced endometrial cancer patients in Europe. Methods: Data were from two multi-center,...
6.
Zhang J, Kelkar S, Prabhu V, Qiao Y, Grall V, Miles N, et al.
BMJ Open
. 2024 Apr;
14(4):e079447.
PMID: 38569701
Objective: To evaluate real-world treatment patterns and clinical outcomes in recurrent/advanced endometrial cancer patients who progressed following prior systemic therapy in clinical practice in Europe. Design: Endometrial Cancer Health Outcomes-Europe...
7.
Wada K, Zhang J, Lee I, Wang Y, Near A, Prabhu V
Future Oncol
. 2023 Oct;
20(5):257-267.
PMID: 37828843
Describe treatment and dosing patterns of lenvatinib and pembrolizumab combination therapy (lenva+pembro) among endometrial cancer (EC) patients in US clinical practice. Retrospective cohort study among adults with EC initiating lenva+pembro...
8.
Lorusso D, Colombo N, Casado Herraez A, Santin A, Colomba E, Miller D, et al.
Eur J Cancer
. 2023 Apr;
186:172-184.
PMID: 37086595
Purpose: Lenvatinib and pembrolizumab (LEN+PEMBRO) demonstrated clinically meaningful and statistically significant improvements in efficacy versus treatment of physician's choice (TPC) in patients with advanced endometrial cancer (aEC) in the phase...
9.
Knisely A, Huang Y, Li Y, Prabhu V, Wright J
Gynecol Oncol Rep
. 2023 Apr;
46:101112.
PMID: 37082519
[This corrects the article DOI: 10.1016/j.gore.2022.101002.].
10.
Stephan A, Reuschenbach M, Saxena K, Prabhu V, Jacob C, Schneider K, et al.
J Health Econ Outcomes Res
. 2023 Feb;
9(1):128-139.
PMID: 36755814
Cervical intraepithelial neoplasia (CIN) can be a consequence of human papillomavirus (HPV) infection. High-grade CIN (CIN2/CIN3) may develop from persistent HPV infection and progress to cervical cancer if left untreated....